|
|
Article: Neurocrine Biosciences Presents Phase III Data at the American Psychiatric Association (APA) Meeting.
- Article from:
- PR Newswire
- Article date:
- May 6, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Results Demonstrate Both Formulations of Indiplon are Safe and Effective in Treating Patients With Chronic and Transient Insomnia
Neurocrine Biosciences, Inc. announced today that four studies were presented this week at the 157th annual meeting of the American Psychiatric Association (APA) demonstrating the efficacy and safety of both formulations of indiplon, immediate release and modified release, in treating patients and subjects with chronic and transient insomnia. The results also show that indiplon is effective across different patient populations including the elderly who frequently suffer from insomnia.
"These data demonstrate that indiplon ...